Abstract P-514

AVJ-514 Trial

severity or improves clinical outcomes in degenerative MR. Degenerative MR is therefore more amenable to surgical therapy. However, many patients are not offered MV surgery because of their high surgical risk status. A percutaneous MV repair device (overseas brand name MitraClip®, Abbott Vascular, Santa Clara, CA, USA) has shown promise in reducing MR severity and improving clinical and functio...

Mol093229 514..521

Canonical transient receptor potential channel 5 (TRPC5) is a nonselective, Ca-permeable cation channel that belongs to the large family of transient receptor potential channels. It is predominantly found in the central nervous system with a high expression density in the hippocampus, the amygdala, and the frontal cortex. Several studies confirm that TRPC5 channels are implicated in the regulat...

Part 514—new Animal Drug Applications

Sec. 514.1 Applications. 514.4 Substantial evidence. 514.6 Amended applications. 514.7 Withdrawal of applications without prejudice. 514.8 Supplemental new animal drug applications. 514.11 Confidentiality of data and information in a new animal drug application file. 514.12 Confidentiality of data and information in an investigational new animal drug notice. 514.15 Untrue statements in applicat...

abstract

ABSTRACT